○ Gyeonggi-do Business and Science Accelerator (GBSA) signed the “Agreement on Biotechnology Transfer and Cooperation in Research” on January 30 with local bio companies including Notox Therapy.
– A total of 6 technologies, including acne and Crohn disease treatments, will be transferred to the companies.
○ Gyeonggi Province Governor Lee Jae-myung: “Gyeonggi Province will provide all possible support for the development of the bio industry, a new future growth engine.”

---

Gyeonggi Province and the Gyeonggi-do Business and Science Accelerator (GBSA) are spurring efforts to enhance the technological capacities of local bio companies and develop future foods.
On January 30, Gyeonggi Province Governor Lee Jae-myung, GBSA CEO Kim Gi-jun, and representatives of eight local bio companies (Notox Therapy, Daeun Medical, Alpha Bio, SI Bio, Oncobix, Kofarm, TEN, Fugen Bio) signed the “Agreement on Biotechnology Transfer and Cooperation in Research” at the Gyeonggi Provincial Government Complex.
The agreement signing ceremony was held to enable the transfer of technologies developed by Gyeonggi Province and GBSA to bio companies based in the region while also promoting research cooperation in the development of new pharmaceuticals and functional products.
The six technologies to be transferred include: snake venom neutralization technology; skin disease prevention/treatment substances; magnolia berry extract index ingredient analysis technology; skin brightening agents derived from Job’s tears bran; substances with acne soothing effects derived from green tea; and inflammatory intestinal disease preventive and therapeutic substances.
Under the agreement, these bio companies will conduct joint research planning and development as well as consulting for the advancement and commercialization of the technologies, while exchanging technologies, knowledge, and information and sharing facilities and equipment with Gyeonggi Province and GBSA through forums, seminars, and workshops.
“R&D and technological development are very important for the advancement of the bio industry, which is closely related to future foods, but they require a great deal of time and money, which makes it difficult for individual organizations such as GBSA and private businesses to perform the entire process independently. Under this agreement, Gyeonggi Province will actively incorporate the opinions of local companies and provide utmost support at a local government level for the development of the bio industry in Gyeonggi Province and the improvement of provincial resident lives,” Gyeonggi Province Governor Lee Jae-myung said.
“Simply transferring new technologies is not just about the development of biotechnologies. More important is the commercialization process. GBSA will strive to promote industry-academia cooperation for the development of biotechnologies and business models in Gyeonggi Province and cooperate with local companies,” GBSA CEO Kim Gi-jun pledged.
Kim Nam-gi, CEO of Alpha Bio, one of Gyeonggi Province’s biotechnology companies, expressed his thanks: “While the Gyeonggi Bio Center has supported us in the R&D and basic science areas, this agreement is expected to support us in the development of health functional substances. With Gyeonggi Province’s support for local companies, we will further our efforts to develop excellent products through this cooperation.”
Meanwhile, Gyeonggi Province and GBSA have jointly promoted the bio industry development support project, established a biomaterial development system, discovered new materials, and supported the research activities of bio companies. They have also developed new therapeutic substances for overcoming drug resistance to lung cancer therapy and for preventing and treating dementia through joint research projects with universities and firms.